Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 44

recruiting
3 968
countries
28
conditions
2 103

3 624 trials match your criteria

Study of Axatilimab compared to standard therapy in children with chronic graft-versus-host disease who have previously received at least 2 treatments

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Axatilimab

Study of KarXT (trospium chloride and xanomeline tartrate) and KarX-EC (xanomeline tartrate) for cognitive impairment in mild to moderate Alzheimer's disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride

Study of xanomeline tartrate and trospium chloride combination for cognitive impairment in people with mild to moderate Alzheimer's disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride

Breast cancer+2

Recruiting

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus

Study of daratumumab, teclistamab and talquetamab combination treatment for frail patients with newly diagnosed multiple myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab

Study of Apitegromab Treatment in Children Under 2 Years Old with Spinal Muscular Atrophy (SMA)

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Apitegromab

Asthma

Recruiting

Study of depemokimab to improve airway function in patients with type 2 eosinophilic asthma

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab

Study of alpelisib in children and adults with PIK3CA-Related Overgrowth Spectrum (PROS)

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib

Breast cancer+1

Recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Rectal cancer

Recruiting

Study of XELOX chemotherapy with or without dostarlimab after chemoradiation in patients with locally advanced rectal cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab

Study of ALXN2350 gene therapy in adults with BAG3 mutation-associated dilated cardiomyopathy: A safety and efficacy trial

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AAV9-CTNT-COBAG3
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.